Additionally, the 36-month beta value for ASBP is 0.83.
The public float for ASBP is 39.39M and currently, short sellers hold a 6.35% ratio of that float. The average trading volume of ASBP on June 26, 2025 was 12.33M shares.
ASBP) stock’s latest price update
Aspire Biopharma Holdings Inc (NASDAQ: ASBP)’s stock price has gone decline by -12.01 in comparison to its previous close of 0.27, however, the company has experienced a -25.66% decrease in its stock price over the last five trading days. accessnewswire.com reported 2025-06-24 that Enrollment Completed on Schedule; Topline Results Expected Mid Q3 2025 ESTERO, FL AND NEW YORK, NY / ACCESS Newswire / June 24, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, today announced the last patient was dosed in its Phase 1 single-center clinical study of its oral transmucosal fast-acting high-dose aspirin formulation. Topline results from the study are anticipated by the middle of third quarter of 2025.
ASBP’s Market Performance
Aspire Biopharma Holdings Inc (ASBP) has seen a -25.66% fall in stock performance for the week, with a 6.49% gain in the past month and a -62.56% plunge in the past quarter. The volatility ratio for the week is 4.77%, and the volatility levels for the past 30 days are at 27.32% for ASBP. The simple moving average for the last 20 days is -37.04% for ASBP’s stock, with a simple moving average of -96.47% for the last 200 days.
ASBP Trading at -37.00% from the 50-Day Moving Average
After a stumble in the market that brought ASBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.48% of loss for the given period.
Stock Fundamentals for ASBP
The total capital return value is set at 0.33. Equity return is now at value -490.07, with -234.69 for asset returns.
Based on Aspire Biopharma Holdings Inc (ASBP), the company’s capital structure generated -4.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.21. The debt to equity ratio resting at -0.82. The interest coverage ratio of the stock is -0.56.
Currently, EBITDA for the company is -11.65 million with net debt to EBITDA at -0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.22.
Conclusion
In conclusion, Aspire Biopharma Holdings Inc (ASBP) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
